Leerink Swann restated their outperform rating on shares of Amicus Therapeutics Inc. (NASDAQ:FOLD) in a research report released on Wednesday morning. The firm currently has a $15.00 target price on the biopharmaceutical company’s stock, down from their prior target price of $17.00.

FOLD has been the subject of several other research reports. Zacks Investment Research cut shares of Amicus Therapeutics from a hold rating to a sell rating in a research note on Tuesday, October 18th. Robert W. Baird restated a hold rating and set a $7.00 target price (down previously from $9.00) on shares of Amicus Therapeutics in a research report on Tuesday. Chardan Capital set a $15.00 target price on shares of Amicus Therapeutics and gave the stock a buy rating in a research report on Thursday, August 11th. Cowen and Company restated an outperform rating and set a $15.00 target price on shares of Amicus Therapeutics in a research report on Tuesday, November 8th. Finally, JPMorgan Chase & Co. restated an overweight rating and set a $11.00 target price (down previously from $12.00) on shares of Amicus Therapeutics in a research report on Wednesday. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the stock. The company presently has a consensus rating of Buy and an average price target of $11.08.

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Amicus Therapeutics (NASDAQ:FOLD) opened at 5.98 on Wednesday. Amicus Therapeutics has a one year low of $4.98 and a one year high of $11.58. The stock has a 50 day moving average of $7.82 and a 200 day moving average of $6.97. The firm’s market capitalization is $851.11 million.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported ($0.33) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.34) by $0.01. The company earned $2.10 million during the quarter, compared to analyst estimates of $1.71 million. Analysts forecast that Amicus Therapeutics will post ($1.38) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The correct version of this news story can be viewed at http://www.dailypolitical.com/2016/12/01/amicus-therapeutics-fold-outperform-rating-reaffirmed-at-leerink-swann.html.

In related news, SVP Daphne Quimi sold 8,546 shares of the business’s stock in a transaction that occurred on Wednesday, November 9th. The shares were sold at an average price of $8.00, for a total value of $68,368.00. Following the completion of the sale, the senior vice president now directly owns 24,189 shares in the company, valued at $193,512. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Hung Do sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 1st. The shares were sold at an average price of $7.00, for a total transaction of $175,000.00. Following the completion of the sale, the insider now owns 533,453 shares of the company’s stock, valued at $3,734,171. The disclosure for this sale can be found here. Insiders own 3.40% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. Candriam Luxembourg S.C.A. increased its stake in Amicus Therapeutics by 14.5% in the second quarter. Candriam Luxembourg S.C.A. now owns 709,900 shares of the biopharmaceutical company’s stock worth $3,876,000 after buying an additional 90,000 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Amicus Therapeutics by 19.8% in the second quarter. Bank of New York Mellon Corp now owns 649,235 shares of the biopharmaceutical company’s stock worth $3,545,000 after buying an additional 107,215 shares during the last quarter. State Board of Administration of Florida Retirement System increased its stake in Amicus Therapeutics by 36.6% in the second quarter. State Board of Administration of Florida Retirement System now owns 55,248 shares of the biopharmaceutical company’s stock worth $302,000 after buying an additional 14,810 shares during the last quarter. DekaBank Deutsche Girozentrale increased its stake in Amicus Therapeutics by 31.5% in the second quarter. DekaBank Deutsche Girozentrale now owns 70,900 shares of the biopharmaceutical company’s stock worth $384,000 after buying an additional 17,000 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. increased its stake in Amicus Therapeutics by 11.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 459,801 shares of the biopharmaceutical company’s stock worth $2,511,000 after buying an additional 48,690 shares during the last quarter.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).

5 Day Chart for NASDAQ:FOLD

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.